Not a good buy right now: price is sitting just above the pivot (~3.03) with only mildly positive but weakening momentum and no clear proprietary buy signals.
Options market shows extremely elevated implied volatility (speculative environment), but with zero volume today—signal quality is weak and pricing is likely inefficient for new entries.
No near-term news catalysts and weak recent fundamentals (sharp YoY revenue drop) reduce conviction for an impatient “buy now” decision.
If you already own it, this is more of a hold/monitor setup unless it cleanly breaks above ~3.16 with follow-through; for a fresh buy today, the data doesn’t justify it.
Technical Analysis
Trend/Momentum: MACD histogram is positive (0.0232) but positively contracting → upside momentum exists but is fading.
RSI(6) = 56.3 (neutral) → no oversold bounce signal; not stretched to the upside either.
Moving averages are converging → consolidation/indecision rather than a clear trend.
Resistance: R1 3.156, then R2 3.231 (needs breakout to confirm strength)
Support: S1 2.911, then S2 2.836 (downside risk if pivot fails)
Pattern-based forecast (similar candlesticks): indicates higher odds of gains over a month (+23.29% chance model output), but near-term is small (+1.9% next day; +2.2% next week) and not supported by strong real-time momentum signals.
Positioning/Sentiment: Put/Call OI ratio 0.09 (calls dominate) → bullish/speculative tilt in open interest.
Liquidity/confirmation: Today’s option volume = 0 (calls 0, puts 0) → today’s sentiment cannot be confirmed by actual flow.
Volatility: 30D IV ~925.4% vs historical vol ~39.65% with IV percentile ~90 / IV rank ~92 → options are priced for extreme moves; this often reflects event/speculation, but no news is present.
Takeaway: options data suggests speculative call-heavy positioning, but the lack of volume makes it a weak real-time buy signal for the stock.
Technical Summary
Sell
6
Buy
4
Positive Catalysts
with MACD still above zero → modestly constructive if it holds.
suggests a bullish skew among outstanding contracts.
Neutral/Negative Catalysts
No news in the last week → no clear event-driven catalyst to justify an immediate buy.
Momentum is weakening: MACD is still positive but contracting; moving averages are converging (chop risk).
Extremely high implied volatility (~925%) can coincide with sharp swings; combined with zero option volume today, it’s not a clean sentiment confirmation.
Congress/politician activity: no recent congress trading data available (no supportive signal).
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: 427,000, down -91.36% YoY → severe top-line contraction.
Net income: -977,000, down -83.22% YoY (still a loss, but loss magnitude improved).
EPS: 0 (0.00% YoY as provided).
Gross margin: 80.33%, down -3.65% YoY → still high margin profile, but trending down.
Overall: fundamentals shown are not supporting a “buy now” decision; growth trend (revenue) is sharply negative.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so the recent Wall Street trend cannot be verified from this dataset.
Wall Street-style pros (based on available data): potential for sharp upside moves (high-volatility profile), call-heavy open interest skew.
Wall Street-style cons (based on available data): steep YoY revenue decline and no identified near-term catalysts; technicals are neutral with fading momentum.
Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.920
Low
12
Averages
12
High
12
Current: 2.920
Low
12
Averages
12
High
12
Jones Trading
Justin Walsh
Strong Buy
to
Hold
Downgrades
n/a
AI Analysis
2025-04-02
Reason
Jones Trading
Justin Walsh
Price Target
n/a
AI Analysis
2025-04-02
Downgrades
Strong Buy
to
Hold
Reason
JonesResearch analyst Justin Walsh downgraded BioLineRx to Hold from Buy without a price target following the Q4 report. BioLineRx is on "sounder financial footing" following cessation of U.S. commercial operations with a cash runway that extends into the second half of 2026, the analyst tells investors in a research note. However, the firm sees the stock remaining range bound until the company's pipeline assets are in-licensed or motixafortide generates additional favorable data in pancreatic cancer and gene therapy indications.
